



PATENT  
ATTENTION: MS AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1600

Confirmation no. 3131  
Atty. Dkt. No. 087147-0494 (new)  
Atty. Dkt. No. 087147-0450 (old)

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

In re reissue application of: U.S. Pat. No. 6,348,481, issued February 19, 2002

Applicants: Yoshiyuki INADA, et al.

Title: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES

Appl. No.: 10/781,263

Filing Date: 02/19/2004

Examiner: Deborah C. Lambkin

Art Unit: 1626

**TERMINAL DISCLAIMER**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Your Petitioner, TAKEDA PHARMACEUTICAL COMPANY LIMITED, having its principal place of business at 1-1-Doshomachi 4-chome, Chuo-ku, Osaka, JAPAN, represents that it is the owner of the entire right, title, and interest in and to U.S. Patent Application No. 10/781,263, filed 02/19/2004, a reissue of U.S. Patent No. 6,384,481, which is based on Application No. 09/758,355, filed on January 12, 2001, by virtue of an Assignment recorded on Reel/Frame 015612/0101, in the United States Patent and Trademark Office, a copy of the Patent Assignment Abstract is attached hereto as APPENDIX A.

08783/2006 JADD01

00000021 10/81263

03 FC:1814

130.00 OP

PATENT  
ATTENTION: MS AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1600

Confirmation no. 3131  
Atty. Dkt. No. 087147-0494 (new)  
Atty. Dkt. No. 087147-0450 (old)

Further, your Petitioner represents that it is the owner of:

(1) U.S. Patent No. 5,721,263, which issued on U.S. Patent Application No. 08/351,011, filed December 7, 1994, by virtue of an Assignment recorded on Reel/Frame 015612/0101, in the United States Patent and Trademark Office, a copy of the Patent Assignment Abstract of Title is attached hereto as APPENDIX B.

Further, your Petitioner represents that it is the owner of:

(2) U.S. Patent No. 5,958,961, which issued on U.S. Patent Application No. 08/883,040, filed June 26, 1997, by virtue of an Assignment recorded on Reel/Frame 015612/0101, in the United States Patent and Trademark Office, a copy the Patent Assignment Abstract of Title is attached hereto as APPENDIX C.

Further, your Petitioner represents that it is the owner of:

(2) U.S. Patent No. 6,228,874, which issued on U.S. Patent Application No. 09/563,855, filed May 4, 2000, by virtue of an Assignment recorded on Reel/Frame 015612/0101, in the United States Patent and Trademark Office, a copy the Patent Assignment Abstract of Title is attached hereto as APPENDIX D.

Your Petitioner, TAKEDA PHARMACEUTICAL COMPANY LIMITED, hereby disclaims the terminal part of the term of any patent granted on the above identified patent application which would extend beyond the full statutory term, as shortened by any terminal disclaimer, of (1) U.S. Patent 5,721,263, (2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874, and hereby agrees that any patent so granted on the above identified patent application shall be enforceable only for and during such period that the legal title to (1) U.S. Patent 5,721,263, (2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874 shall be the same as the legal title to any patent granted on the above identified patent application, this

PATENT  
ATTENTION: MS AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1600

Confirmation no. 3131  
Atty. Dkt. No. 087147-0494 (new)  
Atty. Dkt. No. 087147-0450 (old)

agreement to run with any patent granted on the above identified patent application and to be binding upon the grantee, its successors or assigns.

In making the above disclaimer, Petitioner does not disclaim any terminal part of any patent granted on the above identified patent application, prior to the full statutory terms of (1) U.S. Patent 5,721,263, (2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874 as defined in 35 U.S.C. §§ 154-156 and 173, in the event that (1) U.S. Patent 5,721,263, (2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874 expire for failure to pay a maintenance fee, are held unenforceable or are found invalid in a final judgment by a court of competent jurisdiction, are statutorily disclaimed in whole or terminally disclaimed under 37 CFR § 1.321(a), has all claims canceled by a reexamination certificate or as a result of an interference proceeding, or is otherwise not deemed to provide the rights conveyed by 35 USC § 154, prior to the full statutory term of (1) U.S. Patent 5,721,263, (2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874, as defined in 35 USC §§ 154-156 and 173, except for the separation of legal title stated above. Further, Petitioner does not disclaim any terminal part of a patent granted on the above identified patent application that would extend beyond the present termination of (1) U.S. Patent 5,721,263, (2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874, in the event that such present term is extended by virtue of compliance with the conditions for term extension of any present or future patent term extension provisions of the patent law, including but not limited to 35 U.S.C. §§ 155, 155A or 156, and without waiving Petitioner's right to extend the term of a patent granted on the above identified patent application to the extent provided by law.

The undersigned, being the Attorney of Record for the above identified patent application, and duly authorized to act on behalf of Petitioner, certifies that he has reviewed the Assignments attached as APPENDICES A, B, C and D, and to the best of his knowledge and belief, legal titles to the above identified patent application and (1) U.S. Patent 5,721,263,

PATENT  
ATTENTION: MS AFTER FINAL  
RESPONSE UNDER 37 C.F.R. § 1.116  
EXPEDITED PROCEDURE REQUESTED  
EXAMINING GROUP 1600

Confirmation no. 3131  
Atty. Dkt. No. 087147-0494 (new)  
Atty. Dkt. No. 087147-0450 (old)

(2) U.S. Patent 5,958,961, and (3) U.S. Patent 6,228,874, rest with Petitioners, TAKEDA  
PHARMACEUTICAL COMPANY LIMITED.

The undersigned declares that all statements made herein of his own knowledge are true  
and that all statements made on information and belief are believed to be true; and further that  
these statements were made with the knowledge that willful false statements and the like so  
made are punishable by fine or imprisonment, or both, under Section 1001, Title 18 of the  
United States Code, and that such willful false statements may jeopardize the validity of the  
above-identified application or any patent issuing therefrom.

Respectfully submitted,

Date Feb. 22, 2006

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (202) 672-5569  
Facsimile: (202) 672-5399

By 

Stephen B. Maebius  
Attorney for Applicants  
Registration No. 35,264



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

## Assignments on the Web &gt; Patent Query

**Patent Assignment Abstract of Title**

**NOTE: Results display only for issued patents and published applications.  
For pending or abandoned applications please consult USPTO staff.**

**Total Assignments: 1****Patent #:** [6348481](#)**Issue Dt:** 02/19/2002 **Application #:** 09758355 **Filing Dt:** 01/12/2001**Publication #:** [US20010004640](#)**Pub Dt:** 06/21/2001**Inventors:** Yoshiyuki Inada, Keiji Kubo**Title:** Pharmaceutical composition for angiotensin II-mediated diseases**Assignment: 1****Reel/Frame:** [015612/0101](#)**Recorded:** 01/19/2005**Pages:** 13**Conveyance:** CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).**Assignor:** [TAKEDA CHEMICAL INDUSTRIES, LTD.](#)**Exec Dt:** 06/29/2004**Assignee:** [TAKEDA PHARMACEUTICAL COMPANY, LIMITED](#)

1-1, DOSHOMACHI 4-CHOME

CHUO-KU, OSAKA, JAPAN

**Correspondent:** DAVID J. CUSHING

2100 PENNSYLVANIA AVENUE, N.W.

SUITE 800

WASHINGTON, DC 20037

Search Results as of: 02/17/2006 03:01 PI

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



## United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

## Assignments on the Web &gt; Patent Query

## Patent Assignment Abstract of Title

**NOTE: Results display only for issued patents and published applications.  
For pending or abandoned applications please consult USPTO staff.**

## Total Assignments: 2

Patent #: 5721263 Issue Dt: 02/24/1998 Application #: 08351011 Filing Dt: 12/07/1994

Inventors: YOSHIYUKI INADA, KEIJI KUBO

Title: PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES

## Assignment: 1

Reel/Frame: 007364/0232

Recorded: 02/22/1995

Pages: 2

Conveyance: ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS).

Assignors: INADA, YOSHIYUKI

Exec Dt: 02/09/1995

KUBO, KEIJI

Exec Dt: 02/15/1995

Assignee: TAKEDA CHEMICAL INDUSTRIES, LTD.

1-1, DOSHOMACHI 4-CHOME, CHUO-KU

OSAKA, JAPAN

Correspondent: FOLEY &amp; LARDNER

HAROLD C. WEGNER

3000 K STREET, N.W., SUITE 500

WASHINGTON, D.C. 20007-5109

## Assignment: 2

Reel/Frame: 015612/0101

Recorded: 01/19/2005

Pages: 13

Conveyance: CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).

Assignor: TAKEDA CHEMICAL INDUSTRIES, LTD.

Exec Dt: 06/29/2004

Assignee: TAKEDA PHARMACEUTICAL COMPANY, LIMITED

1-1, DOSHOMACHI 4-CHOME

CHUO-KU, OSAKA, JAPAN

Correspondent: DAVID J. CUSHING

2100 PENNSYLVANIA AVENUE, N.W.

SUITE 800

WASHINGTON, DC 20037

Search Results as of: 02/21/2006 02:25 PM

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

## Assignments on the Web &gt; Patent Query

**Patent Assignment Abstract of Title**

**NOTE: Results display only for issued patents and published applications.  
For pending or abandoned applications please consult USPTO staff.**

**Total Assignments: 1****Patent #:** 5958961    **Issue Dt:** 09/28/1999    **Application #:** 08883040    **Filing Dt:** 06/26/1997**Inventors:** YOSHIYUKI INADA, KEIJI KUBO**Title:** PHARMACEUTICAL COMPOSITION FOR ANGIOTENSIN II-MEDIATED DISEASES**Assignment: 1****Reel/Frame:** 015612/0101**Recorded:** 01/19/2005**Pages:** 13**Conveyance:** CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).**Assignor:** TAKEDA CHEMICAL INDUSTRIES, LTD.**Exec Dt:** 06/29/2004**Assignee:** TAKEDA PHARMACEUTICAL COMPANY, LIMITED1-1, DOSHOMACHI 4-CHOME  
CHUO-KU, OSAKA, JAPAN**Correspondent:** DAVID J. CUSHING2100 PENNSYLVANIA AVENUE, N.W.  
SUITE 800  
WASHINGTON, DC 20037

Search Results as of: 02/21/2006 02:26 PM

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350

[| .HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)



## United States Patent and Trademark Office

[Home](#) | [Site Index](#) | [Search](#) | [Guides](#) | [Contacts](#) | [eBusiness](#) | [eBiz alerts](#) | [News](#) | [Help](#)

## Assignments on the Web &gt; Patent Query

**Patent Assignment Abstract of Title**

**NOTE: Results display only for issued patents and published applications.  
For pending or abandoned applications please consult USPTO staff.**

**Total Assignments: 1****Patent #:** [6228874](#)    **Issue Dt:** 05/08/2001    **Application #:** 09563855    **Filing Dt:** 05/04/2000**Inventors:** Yoshiyuki Inada, Keiji Kubo**Title:** Pharmaceutical composition for angiotensin II-mediated diseases**Assignment: 1****Reel/Frame:** [015612/0101](#)**Recorded:** 01/19/2005**Pages:** 13**Conveyance:** CHANGE OF NAME (SEE DOCUMENT FOR DETAILS).**Assignor:** [TAKEDA CHEMICAL INDUSTRIES, LTD.](#)**Exec Dt:** 06/29/2004**Assignee:** [TAKEDA PHARMACEUTICAL COMPANY, LIMITED](#)

1-1, DOSHOMACHI 4-CHOME

CHUO-KU, OSAKA, JAPAN

**Correspondent:** DAVID J. CUSHING

2100 PENNSYLVANIA AVENUE, N.W.

SUITE 800

WASHINGTON, DC 20037

Search Results as of: 02/21/2006 02:27 PM

If you have any comments or questions concerning the data displayed, contact OPR / Assignments at 571-272-3350

[HOME](#) | [INDEX](#) | [SEARCH](#) | [eBUSINESS](#) | [CONTACT US](#) | [PRIVACY STATEMENT](#)